Boyds is delighted to announce the appointment of Matt O’Connor who joins the company as Senior Manager, Regulatory Affairs.
Matt joins Boyds following more than five years at DLRC, where he gained broad experience across the regulatory lifecycle, supporting regulatory procedures in varied therapeutic areas. He is also a Matt is also a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).
Matt has a PhD from the University of Nottingham, where he researched the molecular misfolding of prion diseases in small ruminants. Prior to working in regulatory affairs, Matt was a post-doctoral research associate at Imperial College London, researching the role of dendritic cells and other components of the immune system in autoimmune conditions such as Crohn’s disease, ulcerative colitis, and multiple sclerosis.
At Boyds, Matt will support clients with regulatory strategy and support their regulatory submissions.
Commenting on joining the Boyds team, Matt says: “I am really excited about this opportunity with Boyds and particularly interested in working on ATMP products with such an expert team. I hope to bring all the experience I have gained over the last five years in regulatory affairs as well as scientific knowledge and understanding, having also worked in academic research, to bring further value to Boyds’ clients.”
Sabine Ruehle, Director, Regulatory Affairs at Boyds, adds: “We are really pleased to welcome Matt to the team. His passion, enthusiasm, and diverse experience in regulatory affairs and medical research will be a great asset to Boyds. We continue to work with a growing number of biotechs and academic groups and Matt’s expertise and insight will play a key role in advancing the development of their medicinal products.”
